When sourcing research compounds for laboratory investigation, selecting a qualified CJC-1295 No DAC supplier requires strict verification of synthetic precision, analytical purity, and lot-to-lot consistency. PX1 Research supplies high-purity CJC-1295 No DAC (Modified GRF 1-29) verified via independent HPLC and mass spectrometry for rigorous in vitro and preclinical research applications.
When sourcing research compounds for laboratory investigation, selecting a qualified CJC-1295 No DAC supplier requires strict verification of synthetic precision, analytical purity, and lot-to-lot consistency. PX1 Research supplies high-purity CJC-1295 No DAC (Modified GRF 1-29) verified via independent HPLC and mass spectrometry for rigorous in vitro and preclinical research applications.
A reliable CJC-1295 No DAC supplier must provide fully documented, transparent analytical verification for every manufacturing lot. Selecting a vendor for preclinical research compounds requires assessing raw material quality, solid-phase peptide synthesis (SPPS) protocols, and third-party analytical testing rather than relying on unverified vendor claims. For biomedical researchers and laboratory procurement specialists, sourcing CJC-1295 No DAC (also categorized as Modified GRF 1-29) demands strict adherence to chemical purity standards, verified sequence integrity, and quantifiable endotoxin control.
PX1 Research operates as a dedicated USA-based research peptide supplier catering exclusively to academic institutions, biotechnology organizations, and analytical laboratories. By maintaining ISO 17025 accredited third-party testing frameworks, batch-specific Certificates of Analysis (COAs), and domestic distribution from California and Arizona facilities, PX1 Research provides the technical documentation and chemical purity necessary for reproducible experimental outcomes.
CJC-1295 No DAC is a synthetic 29-amino-acid peptide analog of naturally occurring Growth Hormone-Releasing Hormone (GHRH). Formally designated as Modified GRF 1-29, its amino acid sequence features four specific substitutions compared to the native GHRH (1-29) sequence: D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27. These amino acid substitutions serve to stabilize the peptide chain against rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), thereby extending its biological half-life in laboratory assays relative to unmodified native GHRH.
Unlike CJC-1295 with DAC (Drug Affinity Complex), the 'No DAC' variant lacks the Lys(Maleimidopropionyl) residue at the C-terminus. Consequently, CJC-1295 No DAC does not form covalent bonds with circulating serum albumin. In laboratory models, this functional distinction yields a significantly shorter elimination half-life (approximately 30 minutes in plasma assays) compared to the extended multi-day half-life observed with the DAC-bound conjugate. Researchers studying non-sustained, pulsatile GHRH receptor stimulation frequently select CJC-1295 No DAC to emulate natural physiological signaling profiles.
In cell-culture and animal models, CJC-1295 No DAC functions as a selective agonist at the GHRH receptor (GHRH-R), located primarily on pituitary somatotropes. Upon ligand binding, GHRH-R activates heterotrimeric G-protein subunits, initiating intracellular cyclic adenosine monophosphate (cAMP) accumulation and protein kinase A (PKA) signaling cascades. This cellular cascade drives transcriptomic expression of growth hormone (GH) genes and triggers exocytosis of stored GH granules.
Preclinical studies suggest that short-acting GHRH analogs like CJC-1295 No DAC facilitate controlled GH release without causing persistent receptor downregulation or desensitization. The elevated circulating GH levels interact with hepatic GH receptors to upregulate synthesis and secretion of Insulin-like Growth Factor 1 (IGF-1). Investigational literature demonstrates that this GHRH-R/GH/IGF-1 signaling axis plays a pivotal role in cellular proliferation, protein translation, nitrogen retention, and extracellular matrix remodeling in tissue repair research models.
To properly contextualize experimental findings, researchers often compare CJC-1295 No DAC against other secretagogues in the GHRH analog and Growth Hormone Secretagogue Receptor (GHSR) agonist classes. Understanding structural and operational differences assists lab managers in selecting the ideal target for specific assay protocols within our complete catalog of research peptides.
When evaluating GHRH receptor ligands, our CJC-1295 No DAC reference standard offers enhanced enzymatic resistance compared to unmodified Sermorelin, which retains the native sequence and degrades rapidly in serum assays. Conversely, Tesamorelin incorporates a hexenoyl moiety to the N-terminal trans-3-hexenoic acid, modifying its lipolytic signaling profile. Furthermore, researchers frequently study GHRH analogs in combination with GHSR agonists such as Ipamorelin to investigate dual-receptor synergistic secretion dynamics in cell culture models. For a detailed molecular comparison, review our guide on CJC-1295 DAC vs No DAC breakdown.
Acquiring high-purity peptides requires looking beyond surface-level claims. A legitimate CJC-1295 No DAC supplier must evaluate every synthesized lot using high-performance liquid chromatography (HPLC) and mass spectrometry (MS). Reversed-Phase HPLC (RP-HPLC) isolates and quantifies the purity percentage of the target sequence by measuring absorbance at 214 nm, verifying that total peptide purity exceeds standard laboratory thresholds (typically ≥98%).
Mass spectrometry (typically Electrospray Ionization MS or MALDI-TOF) provides exact molecular mass verification, ensuring that the synthesized compound matches the target molecular weight of 3367.97 Da without unexpected deletion sequences or incomplete coupling products. Furthermore, for cellular assays sensitive to inflammatory artifacts, biological purity must be validated via Chromogenic Recombinant Factor C (rFC) or Limulus Amebocyte Lysate (LAL) assays to confirm endotoxin levels remain below standard analytical thresholds (<0.01 EU/mg).
PX1 Research mandates rigorous manufacturing and quality control standards across our operational infrastructure. All peptide compounds offered through our platform are synthesized utilizing state-of-the-art automated solid-phase peptide synthesis (SPPS) platforms, followed by multi-stage chromatographic purification to ensure consistent secondary structure and purity.
Every batch of CJC-1295 No DAC undergoes independent, third-party laboratory analysis prior to release. Certificates of Analysis (COAs) containing full RP-HPLC chromatograms and MS spectra are publicly accessible for every lot. Our commitment to chemical integrity extends to domestic fulfillment: all orders are packed under strict temperature-monitored conditions and shipped same-day (Monday through Friday) from our CA and AZ distribution centers. Principal investigators requiring bulk quantities for longitudinal studies can utilize our bulk peptide procurement program to reserve single-lot batches for experimental consistency.
CJC-1295 No DAC is supplied as a sterile, lyophilized cake or powder to ensure optimal long-term chemical stability. To prepare the compound for in vitro testing, researchers should reconstitute the lyophilized powder using sterile target solvents, such as Bacteriostatic Water (0.9% benzyl alcohol) or sterile normal saline, depending on the requirements of the specific cell culture or analytical assay.
Reconstitution protocols should involve introducing the solvent along the inner glass wall of the vial, allowing slow dissolution without aggressive vortexing or mechanical agitation, which can induce peptide aggregation or denaturation. Once reconstituted, aqueous peptide solutions should be aliquoted into single-use microcentrifuge tubes to prevent repeated freeze-thaw cycles and stored at -20°C or -80°C for extended stability. For detailed reconstitutions and solvent compatibility metrics, consult our comprehensive preclinical research library.
Lyophilized CJC-1295 No DAC maintains high chemical stability when stored under controlled environment conditions. For short-term storage prior to reconstitution, solid lyophilized vials should be kept refrigerated at 2°C to 8°C away from direct light exposure. For long-term preservation exceeding 90 days, storing unopened vials at -20°C is recommended to prevent hydrolytic or oxidative degradation of the amino acid residues.
Researchers should ensure that vials reach room temperature before opening or reconstituting to prevent condensation formation on the dry cake, which can introduce moisture and destabilize the peptide matrix. Following these standardized laboratory handling procedures ensures consistent binding kinetics and reproducible assay data across experimental trials.
What is CJC-1295 No DAC, and how does it differ from CJC-1295 with DAC?
CJC-1295 No DAC (Modified GRF 1-29) is a 29-amino-acid GHRH analog that lacks the Drug Affinity Complex (DAC). Without the DAC maleimide linker, it does not bind serum albumin, resulting in a significantly shorter plasma half-life (around 30 minutes) and a pulsatile GH release profile in laboratory models compared to the multi-day half-life of CJC-1295 with DAC.
What analytical tests are provided with PX1 Research CJC-1295 No DAC?
Every lot of CJC-1295 No DAC supplied by PX1 Research includes a third-party Certificate of Analysis (COA) containing Reversed-Phase HPLC (RP-HPLC) purity analysis, Electrospray Ionization Mass Spectrometry (ESI-MS) sequence confirmation, and LAL/rFC endotoxin testing data.
How should lyophilized CJC-1295 No DAC be stored upon receipt?
Unopened, lyophilized vials should be stored at 2°C to 8°C for immediate research use, or at -20°C for long-term storage up to 24 months. Desiccation and protection from direct light exposure are recommended to maintain chemical stability.
What solvents are suitable for reconstituting CJC-1295 No DAC for in vitro assays?
CJC-1295 No DAC is typically reconstituted using sterile Bacteriostatic Water or sterile 0.9% Sodium Chloride solution. For specialized cell culture assays where preservatives are contraindicated, sterile molecular-grade water or phosphate-buffered saline (PBS) may be utilized.
What is the expected analytical purity of PX1 Research peptides?
PX1 Research guarantees a minimum analytical purity of ≥98% as determined by RP-HPLC peak area integration, ensuring minimal sequence truncations or synthesis impurities in your experimental assays.
Can CJC-1295 No DAC be sourced in bulk for long-term research studies?
Yes. PX1 Research offers institutional procurement options and lot-reservation services through our wholesale program, allowing laboratories to secure large single-batch quantities to minimize lot-to-lot variability across longitudinal studies.
Is CJC-1295 No DAC intended for clinical or human consumption?
No. CJC-1295 No DAC provided by PX1 Research is strictly designated for laboratory research use only. It is not intended for human or animal diagnostic, therapeutic, or clinical applications.
How quickly do orders ship from PX1 Research?
Orders placed Monday through Friday ship same-day from our domestic distribution centers in California and Arizona, ensuring minimal transit time for climate-sensitive research compounds.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.